Answer
No. It is an immunotherapy that marks GD2-expressing neuroblastoma cells for immune attack.
Sources for this answer
- Qarziba (Dinutuximab beta) — Current selected SmPCemc · Summary of Product Characteristics
- NHSNHS · NHS medicine guidance
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.